Healthcare Industry News: dialysis
News Release - January 6, 2014
Nikkiso Completes Acquisition of Baxter’s Continuous Renal Replacement Therapy BusinessSAN DIEGO--(Healthcare Sales & Marketing Network)--Nikkiso America, Inc. announced it has completed the acquisition of Baxter International Inc.’s legacy Continuous Renal Replacement Therapy (CRRT) business. CRRT is a therapy used primarily for patients in the ICU in need of blood purification due to acute kidney injury or fluid overload. Nikkiso has been the original equipment manufacturer of the Aquarius™ CRRT System for Baxter and is extending its presence in the acute renal failure marketplace. The company is a global market leader in chronic renal failure equipment.
Under the terms of the transaction, Nikkiso acquired Baxter’s legacy CRRT portfolio, including its acute renal therapy product line: the Aquarius™ System, Aqualine™ and Aquaset™ tubing sets, Aquamax™ hemofilters and Accusol solution. The acquisition also includes the transfer of proprietary Baxter ClearFlex CRRT pharmaceutical solution manufacturing technology and equipment, marketing and distribution rights, intellectual property, and associated agreements. Approximately 85 employees around the world supporting the CRRT business will transfer to Nikkiso, subject to local laws. Final financial terms of the transaction are not being disclosed.
“Nikkiso is a pioneer in blood purification products. For more than half a century, Nikkiso has addressed the needs of caregivers while focusing on improving treatment outcomes for the patients who use these therapies. This acquisition brings Nikkiso’s global position in chronic blood purification therapies together with Baxter’s legacy acute renal therapy product line, providing us with an opportunity to expand our presence in the ICU market,” said Thomas Kelly, President Global CRRT Nikkiso America. The newly acquired global acute renal therapy business will be run out of Nikkiso America, which operates the company’s Medical, Aerospace, and Industrial Divisions in the US.
About Nikkiso Medical
The Medical Division of Nikkiso is one of the world’s leading manufacturers of products for both acute and chronic blood purification therapies. In 1969, Nikkiso developed Japan’s first dialysis machine. Today, based on this time-proven technology, Nikkiso is one of the world’s leading manufacturers of dialysis machines and disposables and a market leader in Europe and Asia. Trusted for superior quality and reliability, over 100,000 Nikkiso devices for blood purification therapies worldwide are currently used by customers around the world. To learn more, visit www.nikkisoamerica.com/medical/.
About Nikkiso America
Nikkiso America, Inc. is headquartered in San Diego, Calif., and has offices and divisions based around the US, operating Nikkiso Co., Ltd.’s US-based Medical, Aerospace and Industrial Divisions. The Divisions specialize in acute blood purification products, chronic dialysis systems, carbon fiber products for aerospace applications, pump products and fluid technologies, water conditioning systems for thermal and nuclear power plants, and particle size characterization. To learn more, visit www.nikkisoamerica.com.
Based in Tokyo, Japan, Nikkiso Co., LTD., is recognized around the world for its 50-year history developing original technologies that span many fields. The company manufacturers exquisitely engineered products from Nikkiso’s Medical, Aerospace, and Industrial Divisions. To learn more, visit www.nikkiso.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.